A twice-yearly injectable drug for HIV prevention, lenacapavir, is a breakthrough advancement in public health. On Wednesday at AIDS 2024, the 25th International AIDS Conference, Linda-Gail Bekker presented the full results from the ‘PURPOSE 1’ trial of twice-yearly injectable lenacapavir for HIV prevention. The new data provides details on the efficacy, safety and tolerability of twice a year lenacapavir injections and were presented at a special late-breaking session at the conference. The data has also been published today in The New England Journal of Medicine. ”The results confirm that lenacapavir…
Tag: HIV
People with HIV have higher risk of contracting Kovid-19: Study
[ad_1] A study conducted by a team of scientists at the Johns Hopkins Bloomberg School of Public Health in Baltimore found that people with HIV (PWH) have an increased risk of successful COVID-19 infection after vaccination. The study’s findings were published online June 7 in JAMA Network Open. While conducting the study, Sally B. Coburn, Ph.D., MPH, and colleagues estimated the rate and risk of success infection in the United States among fully vaccinated PWH and individuals without HIV (PWOH). In addition, data were included for 113,994 patients (33,029 PWH…